Atyr Pharma Stock Performance
| ATYR Stock | 0.75 0.03 4.17% |
The firm shows a Beta (market volatility) of -0.31, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning ATyr Pharma are expected to decrease at a much lower rate. During the bear market, ATyr Pharma is likely to outperform the market. At this point, aTyr Pharma has a negative expected return of -0.46%. Please make sure to confirm ATyr Pharma's sortino ratio, semi variance, as well as the relationship between the Semi Variance and rate of daily change , to decide if aTyr Pharma performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days aTyr Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. Even with unfluctuating performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in February 2026. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors. ...more
Last Split Factor 1:14 | Last Split Date 2019-07-01 |
1 | aTyr Pharma, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights ATYR | 11/13/2025 |
2 | aTyr Pharma Inc. Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit | 11/21/2025 |
3 | Shareholders that lost money on aTyr Pharma, Inc. should contact Levi Korsinsky about pending Class Action - ATYR | 12/02/2025 |
4 | ATYR Deadline ATYR Investors with Losses Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit | 12/03/2025 |
5 | INVESTOR DEADLINE APPROACHING Faruqi Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma | 12/04/2025 |
6 | ATYR 3-DAY DEADLINE ALERT Hagens Berman Urges aTyr Pharma Investors to Act by Dec. 8 Deadline in Suit Over Trial Failure | 12/05/2025 |
7 | ATYR LAWSUIT ALERT The Gross Law Firm Notifies aTyr Pharma, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline | 12/08/2025 |
8 | Is aTyr Pharma In A Good Position To Invest In Growth | 12/18/2025 |
| Begin Period Cash Flow | 26 M | |
| Total Cashflows From Investing Activities | 17.2 M | |
| Free Cash Flow | -69.2 M |
ATyr Pharma Relative Risk vs. Return Landscape
If you would invest 106.00 in aTyr Pharma on October 10, 2025 and sell it today you would lose (31.00) from holding aTyr Pharma or give up 29.25% of portfolio value over 90 days. aTyr Pharma is currently does not generate positive expected returns and assumes 4.5935% risk (volatility on return distribution) over the 90 days horizon. In different words, 41% of stocks are less volatile than ATyr, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
ATyr Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for ATyr Pharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as aTyr Pharma, and traders can use it to determine the average amount a ATyr Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1009
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ATYR |
Based on monthly moving average ATyr Pharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of ATyr Pharma by adding ATyr Pharma to a well-diversified portfolio.
ATyr Pharma Fundamentals Growth
ATyr Stock prices reflect investors' perceptions of the future prospects and financial health of ATyr Pharma, and ATyr Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on ATyr Stock performance.
| Return On Equity | -1.03 | ||||
| Return On Asset | -0.5 | ||||
| Operating Margin | (140.76) % | ||||
| Current Valuation | (4.74 M) | ||||
| Shares Outstanding | 97.99 M | ||||
| Price To Book | 0.91 X | ||||
| Price To Sales | 373.54 X | ||||
| Revenue | 235 K | ||||
| Gross Profit | (61.37 M) | ||||
| EBITDA | (66.37 M) | ||||
| Net Income | (64.02 M) | ||||
| Total Debt | 13.28 M | ||||
| Book Value Per Share | 0.82 X | ||||
| Cash Flow From Operations | (69.12 M) | ||||
| Earnings Per Share | (0.83) X | ||||
| Market Capitalization | 70.97 M | ||||
| Total Asset | 96.83 M | ||||
| Retained Earnings | (532.05 M) | ||||
| Working Capital | 66.99 M | ||||
About ATyr Pharma Performance
Assessing ATyr Pharma's fundamental ratios provides investors with valuable insights into ATyr Pharma's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the ATyr Pharma is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.60) | (0.62) | |
| Return On Capital Employed | (0.75) | (0.78) | |
| Return On Assets | (0.60) | (0.62) | |
| Return On Equity | (1.05) | (1.00) |
Things to note about aTyr Pharma performance evaluation
Checking the ongoing alerts about ATyr Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for aTyr Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| aTyr Pharma generated a negative expected return over the last 90 days | |
| aTyr Pharma has some characteristics of a very speculative penny stock | |
| aTyr Pharma has high historical volatility and very poor performance | |
| aTyr Pharma has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 235 K. Net Loss for the year was (64.02 M) with loss before overhead, payroll, taxes, and interest of (61.37 M). | |
| ATyr Pharma generates negative cash flow from operations | |
| aTyr Pharma has a poor financial position based on the latest SEC disclosures | |
| About 63.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from simplywall.st: Is aTyr Pharma In A Good Position To Invest In Growth |
- Analyzing ATyr Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether ATyr Pharma's stock is overvalued or undervalued compared to its peers.
- Examining ATyr Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating ATyr Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of ATyr Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of ATyr Pharma's stock. These opinions can provide insight into ATyr Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for ATyr Stock Analysis
When running ATyr Pharma's price analysis, check to measure ATyr Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ATyr Pharma is operating at the current time. Most of ATyr Pharma's value examination focuses on studying past and present price action to predict the probability of ATyr Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ATyr Pharma's price. Additionally, you may evaluate how the addition of ATyr Pharma to your portfolios can decrease your overall portfolio volatility.